Phillips-Medisize, a subsidiary of consumer electronics provider Molex, has introduced the Aria Smart Autoinjector platform to advance the digital drug-delivery device market.

The small and simple, smart self injection device features a reusable electronic drive unit and single-use, disposable cassettes to improve patient care while reducing the environmental impact.

Phillips-Medisize said that its Aria Smart Autoinjector is developed with compact size, sound and light signals for operation, simple sleeve-triggered activation and needle safety features.

Also, its reusable drive and disposable cassette help pharmaceutical firms to meet the sustainability target, addressing patient preferences for eco-friendly drug delivery device.

Phillips-Medisize innovation vice president Kevin Deane said: “With the Aria Smart Autoinjector, we are disrupting this sector with a game-changing platform that brings the right functionality to market in the right form factor at the right time.

“Our goal from the outset has been to develop an injector that patients love, combining the simplicity of current disposable devices with the superior performance, sustainability and connectivity possible through an electronic, reusable device.”

Phillips-Medisize is offering the Aria Smart Autoinjector platform in basic and advanced models, to support medication management.

The basic model comes with a simple user interface for standard injection sequences while the advanced model with a screen-based Graphical User Interface (GUI).

With built-in Bluetooth and optional RFID connectivity, the device facilitates easy data sharing of time-stamped dosing logs with smartphones, tablets and mobile healthcare apps.

According to a Molex and Phillips-Medisize survey, more than half of pharmaceutical professionals expect digital drug delivery to improve patient outcomes.

Also, a recent user study underlined Aria’s ease of use, with all of the users experiencing and successfully completing the self-injection without training.

The company said that it is working together with pharma customers to run comparative user studies and assessments, along with development programmes for combination products.